NewAmsterdam Pharma Co N.V. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Douglas Kling, Chief Operating Officer, separated from NewAmsterdam effective August 14, 2026, receiving a 9-month advisor agreement at $50,000/month ($450k total) plus continued vesting of equity through May 14, 2027. Concurrently, Rob Gunning was hired as VP Controller starting August 10, 2026, at $375,000 base salary plus 3,200 RSUs and 14,000 stock options with standard vesting schedules and 30% target bonus.
Why this rating
Leadership transition is material but standard for pharma firms. Kling's ~$450k severance (~3.5% of $1.3B market cap) is modest; new hire fills role at reasonable market rate. No business disruption disclosed; routine replacement of COO.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.